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Abstract
Background: Intermittent preventive treatment in pregnancy (IPTp) delivered during antenatal care (ANC) visits has
been shown to be a highly efficacious and cost-effective intervention. Given the high rates of ANC attendance in
sub-Saharan Africa, the current low IPTp coverage represents considerable missed opportunities. The objective of
this study was to explore factors affecting provider’s delivery of IPTp during ANC consultations.
Methods: Data from five nationally representative service provision assessment surveys informed the statistical
analyses (Kenya, Namibia, Rwanda, Tanzania, and Uganda; 2006-2010). Poisson regression models with robust/
clustered standard errors were used to estimate the effect of different determinants on IPTp delivery from 4,971
observed ANC consultations.
Results: The five major modifiable determinants of IPTp delivery were: 1) user-fees for ANC medicines (relative risk
(RR)= 0.76; 95% confidence intervals (95% CI): 0.62-0.93); 2) facilities having IPTp guidelines (RR =1.12; 95% CI:
1.01-1.24); 3) facilities having implemented IPTp as part of their routine ANC services offering (RR =4.18; 95% CI:
1.75-10.01); 4) stock-outs of sulphadoxine-pyrimethamine (RR= 0.40; 95% CI: 0.27-0.60); and, 5) providers having
received IPTp training (RR= 1.21; 95% CI: 1.09-1.35). Using the population-attributable fraction, it was estimated that
addressing these barriers jointly could lead to a 31% increase in delivery of this intervention during ANC consultations.
Of these four potentially modifiable determinants, training of providers for IPTp had the largest potential impact.
Conclusions: If proved to be cost-effective, dispensing IPTp training to ANC providers should be prioritized.
Multifaceted approaches targeted in areas of low coverage and/or type of facilities least likely to provide this
intervention should be implemented if the Roll Back Malaria target of 100% IPTp coverage by 2015 is to be attained.
Background
Pregnant women are especially vulnerable to malaria as
parasitaemia during pregnancy can lead to serious ad-
verse maternal, foetal, and infant health outcomes [1]. In
sub-Saharan Africa, where malaria burden is concen-
trated, there was an estimated 30 million pregnancies at
risk of this parasitic disease in 2007 [2]. The World Health
Organization (WHO) recommends a three-pronged ap-
proach to address this major public health issue: 1)
prompt and effective case management of clinical malaria
and anaemia; 2) distribution of insecticide-treated bed
nets; and, 3) intermittent preventive treatment in preg-
nancy (IPTp) with sulphadoxine-pyrimethamine (SP) [3].
IPTp consists of presumptive provision of anti-malarials
to pregnant women, shortly after quickening and at inter-
vals of at least four weeks, under the direct observation of
health workers. This intervention has been shown to be
safe and highly effective to prevent maternal anaemia, low
birth weight, and neonatal mortality [4-7], even in areas
of recorded resistance to SP [8]. Further, IPTp delivered
through antenatal care clinics (ANC) is considered very
cost-effective with an incremental cost-effectiveness ra-
tio of $1.02 (2007 USD) per disability-adjusted life-year
averted [9].
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Saharan Africa visit ANC services at least twice during
their pregnancy, the proportion of women receiving at
least two SP doses remained stubbornly low at 22% in
2009-2011 [10,11]. Such missed opportunities to deliver
IPTp through ANC have been described as a ‘failure of
the public health community’ [12]. Further, the actual
coverage levels of IPTp are disconcerting given the Roll
Back Malaria Partnership goal of 80% IPTp coverage
with at least two SP doses by 2010 (and 100% by 2015)
[13] and the President’s Malaria Initiative’s target of 85%
coverage [14].
A systematic review of qualitative studies that explored
barriers to IPTp coverage showed that unclear policy
guidance, drug stock-outs, user fees, poor organization
at health facility, underperformance of healthcare pro-
viders, and low ANC attendance were effectively imped-
ing delivery of this intervention [12]. Other authors have
also suggested that confusion among healthcare pro-
viders, related to the previous WHO guidelines regar-
ding timing and number of IPTp doses, was one of the
key factors influencing coverage of this intervention
[11,15]. These recommendations were recently revised
in an attempt to provide clearer guidance and WHO
now advocates that SP should be provided at each of the
four scheduled antenatal care visits [16]. A recent meta-
analysis found that the number and timing of ANC
visits, parity, education level, socio-economic status,
knowledge about malaria and IPTp, and use of ITN were
key determinants of IPTp uptake at the individual level
[12]. Few interventions have so far been proposed to in-
crease coverage of IPTp. Community-based distribution
could effectively complement ANC-based delivery of IPTp
[17,18] but there is some evidence that this could concur-
rently reduce women’s ANC attendance [19,20]. Potential
alternatives were principally aimed at promoting IPTp in
the community, increasing ANC coverage, and improving
providers’ performance [21-23].
In light of the important gap between ANC attendance
and IPTp uptake, it is hypothesized that interventions
aimed at health providers are likely to be most cost-
effective. A multi-country quantitative analysis of factors
affecting providers’ delivery of IPTp has yet to be con-
ducted, however. The aim of this study is to investigate
providers’ determinants of IPTp delivery in sub-Saharan
Africa. Such information could provide crucial evidence
to effectively design and implement interventions lead-
ing to significant increases in IPTp coverage in malaria-
endemic areas. To this end, service provision assessment
(SPA) surveys, conducted in five countries where a na-
tional IPTp policy was implemented at the time of the sur-
vey (Kenya, Namibia, Rwanda, Tanzania, Uganda), were
used. By comprehensively assessing the preparedness of
health facilities to provide maternal care and collecting
detailed and standardized information on the performance
of IPTp delivery systems, these nationally representative
surveys provide a unique opportunity to explore supply-
side determinants of IPTp delivery.
Methods
SPA surveys have been conducted by The DHS Program
since 1999 in 11 countries so far. Standardized method-
ology and instruments are used to provide comparable
information on key indicators of formal sector health
services related to child health, maternal and newborn
health, family planning, selected infectious diseases ser-
vices, basic surgery, and non-communicable diseases. As
such, pharmacies and individual doctor’s practices are
not usually included in these surveys. SPA surveys consist
of four main questionnaires: 1) an inventory questionnaire
that collects information on availability of different ser-
vices and general service readiness at the health facility; 2)
a health worker interview questionnaire; 3) an observation
protocol of client-provider consultations for selected ser-
vices; and, 4) an exit interview questionnaire for clients of
these selected services.
Inclusion criteria
Only recent surveys conducted after 2000, that imple-
mented the observation protocol for ANC client-provider
consultations, and that were performed at a time when
the country had implemented a national IPTp policy were
included. For this reason the SPAs from Namibia and
Rwanda are included in this study even though they
abandoned their national IPTp policy in 2010 and 2008,
respectively, following important declines in malaria
transmission experienced by these two countries. Hence,
data on delivery of IPTp and its determinants came from
five SPA surveys conducted between 2006 and 2010 in
Kenya (2010) [24], Namibia (2009) [25], Rwanda (2007)
[26], Tanzania (2006) [27], and Uganda (2007) [28]. The
Kenya 2004 SPA [29] was not included because inter-
viewers did not record whether anti-malarial prophylaxis
was observed to be administered as directly observed ther-
apy (DOT) or only prescribed to the ANC clients.
Survey design
The sampling for each SPA was designed to allow for in-
dicators to be representative at the national and regional
levels, by type of facility and by managing authority. The
sample of facilities selected for inclusion was obtained
from a master list of all health facilities. National referral
hospitals and regional general hospitals are often over-
sampled, as well as facilities providing specific services.
Survey weights are assigned to each facility to correct
for such differential sampling. Three of the included SPA
surveys used this design. In contrast, Namibia performed
a census of all its health facilities, and Rwanda included all
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ities with at least five employees, and one third of private
facilities with three or four employees.
Providers of health services were sampled among
those who were present in the facility on the day of the
survey and who provided the services being assessed by
the SPA survey. The target was to interview an average
of eight providers by facility, including all those whose
consultations were observed. Sampling weights were con-
structed in order to account for differential sampling of
providers with distinct qualifications in a facility type and
region. The sample of health providers was generally con-
sidered representative of the staff who provides the ser-
vices being assessed, except in the very few instances
when a special training event or evaluation for a group of
workers would have taken them away from their post on
the day of the survey.
It is generally difficult to obtain a sampling frame of
eligible clients that would attend the assessed services
on any particular day. Therefore, the SPA surveys used a
convenience sample of clients for the observation pro-
tocols and exit interviews. Specifically, clients were se-
lected as they arrived for consultations at the facility.
When multiple eligible clients were available, intervie-
wers selected two new clients for every follow-up case.
A target of five clients was included, with a maximum of
15 observations in any given facility for each assessed
service. Exit interviews were attempted for every client
observed during a consultation. All SPA surveys used
this sampling design except the 2010 Kenyan SPA. For
this latter survey, clients entering the facility were syste-
matically sampled until a maximum of five observations
per provider were obtained and no more than 15 obser-
vations in any given facility for each service. Sampling
weights used the facility weights described above and ad-
justed for over-representation of observations based on
the compiled total number of clients of each service of
interest seen on the day of the survey (note that facility,
providers and clients’ sampling weights are not provided
in the Rwanda 2007 SPA). In a few instances, the sample
of clients present on the day of the survey might not be
representative of clients normally receiving health ser-
vices if the survey coincided with special events such as
a health fair or campaign.
Data processing
Databases with observations of ANC consultations and
exit interviews were linked to the provider’s interview
and facility questionnaires using their unique identifiers.
Although the survey instruments described above were
standardized, country differences in the classification of
the different facility types and of a provider’s qualifica-
tions exist. Hence, the classification of these variables
was harmonized according to the criteria described in
Additional file 1 before merging the five SPAs together.
The variables considered in this study were:
Facility level: 1) facility type; 2) managing authority
(public vs private); 3) whether the facility charged user-
fees for medicines given during ANC consultations (yes/
no, as reported by the manager of ANC services); 4)
whether the facility had guidelines or protocol for IPTp; 5)
whether the manager of ANC services claimed that IPTp
was routinely offered to antenatal clients; and, 6) whether
the facility had tablets of SP (Fansidar, Metakelfin, Orodar)
available in its inventory on the day of the survey (stock-
outs are defined as not having SP in the inventory on the
day of the survey). Information on these variables was ex-
tracted from the facility questionnaire.
Provider level: 1) professional/technical/medical qua-
lification of the provider; 2) whether the provider repor-
ted to have received supervision or technical support
from a supervisor in the facility or outside of the facility
in the previous six months; and, 3) whether the provider
had received any pre-service or in-service training for
IPTp in the preceding year. Information on these vari-
ables was extracted from the providers’ questionnaire.
Client level: 1) whether the provider administered anti-
malarial prophylaxis as DOT (as observed by the inter-
viewer); 2) primigravidae status; 3) whether it was the first
ANC visit at the facility for the current pregnancy; 4) edu-
cation level; 5) age; and, 6) length of pregnancy (weeks).
Information on these variables was extracted from the ob-
servation protocol of client-provider consultations and the
clients’ exit interview questionnaire.
Namibia’s IPTp policy only targeted its malaria-endemic
areas and observations of consultations outside these
areas were therefore excluded. Similarly, the policy in
place in Kenya during the 2010 SPA specifically tar-
geted three provinces where malaria was most endemic
(Nyanza, Coast, and Western) [24] but the decision to
include observations from all provinces was made be-
cause IPTp delivery did not differ between the target
and non-targeted provinces (i.e., 44 vs 42%). Finally, be-
cause IPTp administration should be avoided in the
first trimester (i.e., before quickening), only consulta-
t i o n sf r o mc l i e n t st h a tw e r e1 6w e e k sp r e g n a n to rm o r e
were included.
Statistical analyses
The main outcome is whether the provider was observed
to provide anti-malarial prophylaxis as DOT during an
ANC consultation (hereinafter referred to as IPTp).
The frequency of this outcome was high and reporting
odds ratio will overstate the relative risk (RR) association -
the quantity of interest for public health research. Log-
Poisson models provide consistent estimates of RR but, in
case of common binary outcomes, Poisson errors will
overestimate binomial errors if a robust error variance is
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that used generalized estimating equation to perform the
unbiased variance estimation, taking into account cluster-
ing of observations within providers and facilities [31,32],
was adopted. This model takes the following form:
Yijk e Poisson πijk
  
log πijk
  
ﾼ α þ ʲ Facilityk
  
þ ʴ Providerj
  
þ ʳ Individuali ðÞ
þˉ Countryk
  
þ ʵijk
where πijk is the probability that women i is being given
anti-malarial prophylaxis by provider j in facility k; α is
the intercept; ʲ is a vector of coefficients for facility-level
variables; ʴ is a vector of coefficients for provider-level
variables; ʳ is a vector of coefficients for the individual
women’s variables; and ˉ is the vector of coefficients for
country fixed effects. Robust standard errors were ob-
tained using an exchangeable correlation structure at the
facility level. Because observations of client-provider’s
consultation are perfectly nested within facilities, cluster-
ing the standard errors at this upper level through the
sandwich variance estimator will also take into account
clustering of consultations at the provider level [33]. Fol-
lowing the rationale of Solon et al.[ 34], who discussed
three situations where using sampling weights is justified
(none of which applied to the present case), sampling
weights were not used in the regression analyses.
Exploratory data analyses suggested that the relation-
ship between the outcome and week of pregnancy was
not linear. The functional form of this variable was hence
modelled using a cubic b-spline with five degrees of free-
dom. Observations with missing values for the outcome
were excluded from the analysis and covariates with miss-
ing observations were retained in the analysis using the
missing indicator method [35]. All variables were first en-
tered in univariate models before the full multivariate
model was fit. Pooling data from these five countries was
deemed appropriate as key barriers to delivery of IPTp
have been shown to be relatively consistent across coun-
tries [12]. Further, preliminary analyses of separate regres-
sion models for each country, where confidence intervals
of the estimates were overlapping, suggest that there was
no significant effect modification by country (Additional
file 2). All analyses were performed using the R statistical
software [36], and the ‘geepack’ package [37] was used to
fit the modified Poisson regression models with clustered
standard errors.
In order to quantify the contribution of selected poten-
tially modifiable determinants of IPTp delivery (defined as
the provision of any dose of IPTp-DOT), the population
attributable fraction (PAF) was estimated. The PAF quan-
tifies the proportional increase in IPTp delivery during
ANC consultations that would have occurred if a barrier
to delivery had been completely removed or a driver fully
scaled-up. The following equation was used to compute
this metric:
PAF ﾼ
RR− P0 þ P1 RR ðÞ ﾽ 
P0 þ P1 RR ðÞ
where RR is the relative risk for the selected determin-
ant; P0 is the proportion of the currently non-exposed
population; and P1 is the proportion of the currently
exposed population. The exposed and unexposed pro-
portions of the population were calculated using the
appropriate sampling weights. These weights were mul-
tiplied by the number of reported ANC visits per month
for each facility to obtain estimates representative of all
women seeking ANC services. The five surveys were com-
bined and each survey was re-weighted proportionally to
the size of its country's female population. For cases where
the determinant was a barrier (i.e., RR<1), the coding of
the exposure was reversed so that the reference exposure
(non-exposed) is changed to the exposed and the inverse
of the RR was inputted in the modified PAF formula. Un-
certainty intervals (UI) for this modified version of the
PAF were obtained using 10,000 Monte Carlo simulations.
Finally, the joint contribution of multiple modifiable
determinants of IPTp delivery, taking into account their
potential correlation, was assessed. Because preliminary
analyses have shown that the selected determinants do
not interact on the multiplicative scale, their joint con-
tribution was estimated using a multiplicative excess risk
scale. The joint PAF for multiple determinants was com-
puted by summing the combined RR of individual re-
cords using the appropriate survey weights [38]. This
joint PAF was calculated using the following formula:
Joint PAF ﾼ
X
RRi
0−
X
RR
i X
RR
i
where RRi
0 ﾼ exp
X n
jﾼ1
ʲj Xij
0   
"#
and RRi ﾼ exp
X n
jﾼ1
ʲj Xij
  
"#
where ʲj corresponds to the log RR per unit of exposure
of determinants j; Xij’ is a vector that contains the alter-
native distribution of determinants j for each record i
(for this study, binary determinants were set to 1, corre-
sponding to the situation were all providers would be
exposed); and Xij is the current distribution of determin-
ant j for each record i. As for the individual PAF, the
coding of barriers (i.e., RR <1) was reversed and the in-
verse of the RR was used. To calculate uncertainty inter-
vals for the joint PAF, 10,000 log-RR from a multivariate
normal distribution were first simulated. These Monte
Carlo simulations were then combined with 10,000 boot-
strap replicates of the current exposure distribution,
implicitly modelling the correlation structure of the dif-
ferent exposures and defining the sampling unit at the
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tions. These analyses were also performed using the R
statistical software [36].
Results
A total of 2,746 health facilities were surveyed in the five
combined SPA surveys, of which 2,200 provided ANC
services (Figure 1). Among these, 1,577 were offering
this type of services on the day of the survey and 1,310
health facilities were further selected for the maternal
health subsurvey with observations of client-provider’s
ANC consultation and client exit interviews. After ex-
cluding observations of consultations performed in non-
malarious areas of Namibia (n =190), those for women
less than 16 weeks into their pregnancy (n= 251), and
those for which the main IPTp outcome was missing
(n = 55), a total of 4,976 observations of client-provider
consultations contributed information to the analyses.
These consultations were performed in 1,285 different
facilities by 1,438 unique providers. The great majority
of facilities (89.9%) had only one provider contributing
information and each provider had an average of 3.5
observed ANC consultations.
The characteristics of facilities, providers and clients
are described in Table 1. Anti-malarial prophylaxis was
administered as DOT in only 35% of all consultations.
There were important variations in the proportion of
different types of facilities surveyed between countries,
reflecting national differences in health system delivery
of ANC services. For example, 94.6% of facilities provid-
ing ANC services in Rwanda were health centres, but
this proportion dropped to 8.3% in Tanzania. Namibia’s
health system is almost entirely public and less than 1%
of facilities in malarious areas of this country charged
user-fees for ANC medicines. In contrast, private prac-
tices and user fees were more common in Kenya. Over-
all, 93% of the surveyed facilities claimed to routinely
provide IPTp as part of their ANC services but this pro-
portion varied from a low of 73% in Namibia to a high
of 99% in Uganda. SP was not available in 11% of the fa-
cilities on the day of the survey. The great majority of
providers of ANC services were either enrolled nurse/
midwife (36%) or registered nurse/midwife (42%), and
only 26% of all providers had received IPTp training in
the year preceding the survey.
Results from univariate and multivariable regressions
(Figure 2) show that hospitals and health centres did
not differ much in their propensity to deliver IPTp but
health posts and dispensary were 20% less likely to de-
liver IPTp as compared to health centres. Providers
Figure 1 Flowchart of the inclusion of the health facilities, providers, and clients of ANC services in the service provision assessments
survey of Kenya, Namibia, Rwanda, Tanzania, and Uganda (2006-2010).
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pregnant) for five service provision assessment surveys conducted in sub-Saharan Africa
Variables Kenya 2010 Namibia 2009 Rwanda 2007 Tanzania 2006 Uganda 2007 All combined
Facility N=394 N =165 N=149 N=372 N= 205 N= 1,285
Facility type
Health centre 25.6% 19.4% 94.6% 8.3% 27.3% 28.1%
Hospital 52.0% 2.4% 2.7% 30.1% 41.0% 31.8%
Health post/dispensary 22.3% 78.2% 2.7% 61.6% 31.7% 40.1%
Public facility 67.3% 99.4% 70.5% 80.4% 77.1% 77.1%
Facility has fee for medicines 31.7% 0.6% 4.7% 4.3% 3.9% 12.2%
Missing 0.5% 0.0% 5.4% 0.0% 0.5% 0.9%
Facility has IPTp guidelines 53.0% 3.0% 50.3% 51.3% 47.8% 45.0%
Facility claims routine IPTp 95.2% 72.7% 96.0% 94.6% 99.5% 92.9%
Missing 0.0% 0.0% 0.0% 0.5% 0.0% 0.2%
SP stocked-out on visit day 8.6% 22.4% 10.7% 12.1% 6.8% 11.4%
Missing 0.8% 0.6% 0.0% 0.8% 0.0% 0.5%
Provider N=461 N =210 N=149 N=405 N= 213 N= 1,438
Type of provider
Physician 5.9% 0.0% 2.0% 5.7% 3.3% 4.2%
Enrolled nurse/midwife 47.5% 59.5% 2.7% 14.1% 50.2% 35.6%
Registered nurse/midwife 42.7% 38.6% 79.2% 34.6% 33.8% 42.3%
Other 2.4% 1.0% 15.4% 44.4% 7.0% 16.1%
Missing 1.5% 1.0% 0.7% 1.2% 5.6% 1.9%
Supervised in last 6 months 78.3% 70.5% 86.6% 78.8% 79.3% 78.3%
Missing 1.7% 1.0% 1.3% 1.2% 6.1% 2.1%
Trained for IPTp in last year 31.2% 25.7% 30.2% 16.5% 32.4% 26.3%
Missing 2.2% 1.0% 0.7% 1.2% 6.1% 2.2%
Consultations/clients N=1,371 N =637 N=669 N=1,546 N= 753 N= 4,976
IPTp administered as DOT 41.8% 8.0% 59.0% 25.4% 42.0% 34.7%
Prescribed/Given IPTp 67.5% 19.1% 69.3% 49.1% 65.2% 55.4%
Missing 0.2% 0.3% 1.0% 0.1% 0.5% 0.3%
Primigravidae 31.1% 35.2% 28.7% 24.3% 30.5% 29.1%
Missing 1.0% 0.2% 0.6% 0.1% 0.3% 0.4%
First visit at facility 38.9% 50.7% 50.2% 39.4% 46.6% 43.2%
Missing 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
Education
None 8.2% 11.9% 35.1% 21.9% 19.8% 18.3%
Primary 49.9% 25.0% 54.9% 66.7% 48.5% 52.4%
Secondary/Higher 39.2% 63.1% 7.8% 11.3% 29.0% 27.8%
Missing 2.7% 0.0% 2.2% 0.1% 2.8% 1.5%
Age
<20 years 13.7% 21.5% 4.0% 15.5% 21.1% 15.1%
20-29 years 63.4% 49.5% 59.2% 57.8% 56.8% 58.3%
≥30 years 19.9% 25.7% 34.4% 26.6% 19.1% 24.6%
Missing 3.0% 3.3% 2.4% 0.2% 2.9% 2.1%
Weeks of pregnancy (mean) 29.9 27.9 26.5 27.9 28.8 28.4
Descriptive statistics do not take into account survey weights.
ANC = antenatal care; IPTp= intermittent preventive treatment for malaria in pregnancy; DOT = directly observed therapy.
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likely to provide anti-malarial prophylaxis to their ANC
clients. Importantly, user-fees for ANC medicines seem
to deter client from receiving IPTp in both univariate
and multivariable analyses with an adjusted RR of 0.76
(95% confidence interval (95% CI): 0.62-0.93). Having
IPTp guidelines or protocols in the facilities was also
associated with increased delivery of this intervention
(RR= 1.12; 95% CI: 1.01-1.24). Unsurprisingly, the fac-
tor whose effect was greatest was whether the facility
claimed that IPTp was routinely offered as part of their
ANC services. Such facilities were close to four times
more likely to deliver this intervention. An important
barrier to IPTp was stock-outs of SP on the day of the
survey. Consultations occurring in stocked-out facilities
were 60% less likely (RR =0.40; 95% CI: 0.27-0.60) to
deliver IPTp. Even if SP was stocked-out in the facility’s
inventory on the day of the survey, providers could
have administered IPTp if a separate supply was kept in
the office were ANC consultations occurred, explaining
why some women still received IPTp in stocked-out
facilities.
Figure 2 Univariate and multivariable results of the modified Poisson regression model of providers’ determinants of delivery of
intermittent preventive treatment for malaria in pregnancy administered as directly observed therapy (N= 4,971).
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deliver the IPTp intervention. Providers with other qualifi-
cations did not exhibit much difference in their estimated
effect size measures. Providers who had been supervised
in the previous six months were not more likely to deliver
IPTp during a consultation. In contrast, providers who
have received IPTp training during the previous year were
21% more likely to give anti-malarial prophylaxis during
ANC visits (RR: 1.21; 95% CI: 1.09-1.35). Providers whose
clients were seeking ANC services for the first time in
their current pregnancy were 52% (RR=1.52; 95% CI:
1.39-1.66) more likely to give them IPTp while age of the
client was not statistically significant in the multivariable
analysis. Finally, clients in their 20
th to 32
nd week of preg-
nancy were the most likely to receive IPTp.
All these results were robust to different model speci-
fications. Specifically, the different effect size measures
were robust to the inclusion of 60 dummy variables re-
presenting the different subnational regions (Additional
file 3). Including fixed effects at the regional level could
effectively account for unmeasured differences in malaria
endemicity levels or regional targeting by national malaria
control programmes. Further, restricting the analyses to
consultations from providers working in facilities where
IPTp was claimed to be routinely offered as part of their
ANC services had no impact on the other determinants’
point estimates (Additional file 4). Finally, when the out-
come was defined as providers prescribing or giving anti-
malarial prophylaxis – without considering if it was
administered as DOT – all determinants remained sta-
tistically significant (except for the availability of IPTp
guidelines/protocols), although the point estimates were
generally closer to the null (data not shown).
To get a measure of potential impact, the proportional
increase in IPTp delivery that would occur if selected
barriers would have been removed or if drivers would
have been fully scaled was estimated. Among the covari-
ates that were found to be significant in the multivari-
able regression model, the following determinants were
considered potentially modifiable: 1) removing user-fees
for ANC medicines; 2) providing all facilities with IPTp
guidelines/protocols; 3) implementing IPTp as part of
the routine ANC services in all facilities; 4) preventing
stock-outs of SP; and, 5) providing annual IPTp-specific
training to ANC providers. As such, providers’ qualifica-
tions and client-level determinants such as education,
age, weeks of pregnancy, or primigravidae status are not
considered modifiable.
The modified PAF showed that, if the estimated effect
size measures have a causal interpretation, removing user-
fees for ANC medicines would have a negligible impact
on delivery of IPTp (Table 2). This is not entirely sur-
prising since the great majority of facilities in the five sur-
veyed countries were not applying any charges. Similarly,
providing IPTp guidelines/protocols to facilities would re-
sult in a 5.5% increase in IPTp delivery. Implementing
routine IPTp in all facilities would increase by only 3.2%
the delivery of IPTp during consultations, as 96% of facil-
ities already offered IPTp as part of their ANC services.
Preventing SP stock-outs would have a more important
impact, increasing delivery of this intervention by 6.8%.
These analyses suggest, however, that annual training of
ANC providers for IPTp would have the biggest impact
on IPTp delivery with an estimated 13.9% increase. Over-
all, addressing these five barriers/drivers jointly would
result in a 30.6% (95% UI: 20.7-44.2%) increase in the
proportion of client consultations where anti-malarial
prophylaxis would have been administered as DOT.
Discussion
ANC attendance in sub-Saharan Africa has been referred
to as a success story [39]. Among the five countries ana-
lysed in this paper, coverage for at least two ANC visits
approximated 90% (Table 3). Coverage of IPTp, however,
was much lower, varying between 11 and 27% according
to demographic and health survey data. As current guide-
lines recommend a minimum of four antenatal visits, this
IPTp gap represents considerable missed opportunities to
deliver a cost-effective intervention. This paper has shown
that the main potentially modifiable determinants of pro-
viders’ delivery of IPTp were the absence of user-fees for
ANC medicines, availability of IPTp-specific guidelines/
protocols in the facility, whether a facility claimed to
routinely offer IPTp as part of their ANC services, the
absence of SP stock-outs, and providers being recently
trained for IPTp. The respective impact of these deter-
minants on the expected proportional increase in IPTp
delivery varied importantly, however. Training providers
Table 2 Proportional increase attributable to selected
modifiable determinants of intermittent preventive
treatment for malaria in pregnancy delivery
Barriers/Drivers Current
prevalence*
Proportional increase
in IPTp (95% UI)
Removing user-fees for ANC
medicines
12.2% 3.1% (1.4-6.5%)
Providing IPTp guidelines to
all facilities
50.1% 5.5% (1.9-15.1%)
Integrating IPTp in routine
ANC services
96.0% 3.2% (1.8-5.2%)
Preventing stock-outs of SP 10.7% 6.8% (4.1-10.4%)
Annual IPTp-training for
providers
30.2% 13.9% (7.5-24.8%)
Joint effect 30.6% (20.7-44.2%)
UI=uncertainty intervals; SP=sulphadoxine-pyrimethamine; IPTp=intermittent
preventive treatment for malaria in pregnancy; ANC=antenatal care.
*Prevalence estimates take into account the appropriate survey weights that
were multiplied by the facility's number of ANC visits per month to represent
the distribution of consultations for which the barrier/driver was present.
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14% increase in delivery during ANC consultations. Ad-
dressing these five barriers/drivers jointly would increase
the proportion of consultations where IPTp is delivered
by 31%. These estimates depend strongly on the current
distribution of these determinants, however, and coun-
tries where barriers are more common should expect
higher impact (country-specific estimates can be found
in Additional file 5).
The fact that addressing these five determinants jointly
would only lead to a 31% increase in IPTp delivery war-
rants further discussion as it emphasizes that no single
determinant is responsible for the IPTp gap. Other fac-
tors, not measured in SPA surveys, could be important
barriers to IPTp delivery. These include the unavailabil-
ity of potable drinking water to swallow the SP tablets
and/or sharing of drinking cups among clients [45,46];
providers having high workload, low motivation, and/or
being poorly organized [46-48]; providers’confusion about
timing and number of IPTp doses [11,23]; women’s previ-
ous experiences of SP-related side effects and/or fear of
side effects [49,50]; women refusing to take the tablets on
an empty stomach [12,45]; and, women’s perception of
malaria risk and their lack of knowledge about the benefits
of IPTp [12,51,52]. Although the last three barriers do not
correspond to supply-side determinants, providers could
help mitigate/overcome them by providing women with
appropriate information during their ANC consultation
on the role, innocuity, and importance of IPTp.
Among the determinants that were not deemed to be
modifiable, it was found that publicly managed facilities
had higher rates of IPTp delivery than private ones. This
could result from IPTp guidelines being easier to imple-
ment in public facilities as they are under the direct con-
trol of national authorities. The consequence being, as
was observed in Nigeria, that providers from private fa-
cilities have incorrect knowledge of IPTp recommen-
dations [53]. Further, local health authorities in Tanzania
acknowledged that preferential treatment was provided
to public facilities when it came to budget allocation for
IPTp as they feared commercialization of this health ser-
vice in private facilities [54].
The data showed that providers were 52% more likely
to deliver IPTp if this was the client’s first ANC visit at
the facility for their current pregnancy (conditional on
being 16 weeks pregnant or more). Unclear policy and
guidance for IPTp has been identified as a key barrier to
effective delivery of this intervention and providers’ con-
fusion about timing of the second SP dose could explain
this result [12,55]. In addition, providers were less likely
to provide IPTp to women outside the 20
th to 32
nd weeks
of pregnancy range. Tanzania and Namibia used an IPTp
schedule that differed from WHO recommendations
and this could have contributed to the observed pattern
[56,57] (i.e., administering IPTp between 20-24 and 28-32
weeks of gestation for Tanzania and between 26-28 and
34-36 weeks of gestation for Namibia).
Clinicians were the least likely to deliver IPTp to their
clients. In ANC settings, these providers generally dis-
pense palliative care for symptomatic pregnant women
where IPTp might be contraindicated. Alternatively, it is
also possible that nurses and midwives are more cogni-
zant of the recommended standards of care and correctly
apply the IPTp protocols. The fact that supervision of pro-
viders, a proxy for improved management practices, was
not found to impact delivery of the intervention should
not be taken at face value as the estimates could be af-
fected by reverse causality. That is, underperforming
providers that do not follow guidelines might attract
supervisory attention.
This study has a number of limitations. First, several
demand-side determinants of IPTp uptake were not col-
lected by the SPA surveys. These include, for example,
individual malaria risk perceptions and knowledge of
benefits of anti-malarial prophylaxis during pregnancy.
Although the omission of such important determinants
contributes to increasing the standard errors of the esti-
mates, they are likely not correlated to provider’s charac-
teristics (conditional on the covariates included in the
model) and should not bias the results. Second, informa-
tion on the number and timing of the preceding dose(s)
of SP, if any, was not available. The guidelines in effect
at the time of the surveys recommended two doses of SP
during the second and third trimester of pregnancy –
Table 3 Mothers’ attendance of antenatal care and uptake of IPTp in the five selected countries
Country Sample size* ≥1 ANC visit ≥2 ANC visits ≥1 dose of SP ≥2 doses of SP Reference
Kenya 3,973 and 2,264 92.7% 88.4% 35.5% 15.1% DHS 2008-09 [40]
Namibia 3,898 and 2,054 96.2% 94.5% 27.8% 10.6% DHS 2006-07 [41]
Rwanda 3,658 and 2,267 97.3% 91.4% 53.0% 17.7% DHS 2007-08 [42]
Tanzania 5,519 and 3,266 98.0% 94.4% 63.3% 27.2% DHS 2010 [43]
Uganda 4,958 and 3,092 95.7% 91.7% 48.4% 26.7% DHS 2011 [44]
ANC = antenatal care; SP= sulphadoxine-pyrimethamine; DHS = demographic and health survey.
*The first listed sample size corresponds to the denominator used to calculate ANC attendance and the second to the denominator use to estimate coverage of
IPTp with SP. The sample sizes differ because the recall period for ANC attendance and IPTp coverage is for the most recent live birth over the last five years
versus the last two years, respectively.
Maheu-Giroux and Castro Malaria Journal 2014, 13:440 Page 9 of 12
http://www.malariajournal.com/content/13/1/440with the exception of Kenya, which in 2006 recom-
mended administration of IPTp at each scheduled ANC
visits after quickening [58]. Hence, some of the clients
could have been ineligible for IPTp if they had already
received their two doses or if they had received their
first one within the preceding four weeks. Coverage of
two or more doses of IPTp is rather low in these coun-
tries (Table 3), however, and the likelihood that wo-
men were eligible for a third dose is small. Further,
the four recommended ANC visits are usually sched-
uled at least one month apart, which would have also
minimized the number of women ineligible for IPTp
because their preceding dose was administered within
the proscribed period. Another scenario for which
women might have been ineligible for IPTp consists of
SP being contra-indicated in HIV-infected women re-
ceiving co-trimoxazole (CTX) prophylaxis (but not those
taking antiretroviral therapy). The proportion of women
ineligible for IPTp based on CTX prophylaxis should be
small, however, as implementation of this intervention
has been slow in resource-limited settings [59]. Third,
providers knew that they were being observed and the
Hawthorn effect [60] could have affected the outcomes
of ANC consultations. The most likely direction of this
effect is that providers would have been more prone to
administer anti-malarial prophylaxis, in which case the
proportion of ANC consultations for which IPTp is
given is probably lower than that reported in the sur-
veys. However, if this effect is not correlated with the
characteristics of the facility, the provider, or the client,
then the effect size estimates should not be biased.
Lastly, the proportional increase estimates derived from
the PAF calculations assumes that the effect size mea-
sures have a causal interpretation. The lack of exogen-
ous variation for the selected modifiable determinants
prohibits such a strong causal claim. Yet, the estimates
were robust to different model specifications and these
determinants have been identified previously in both
qualitative and quantitative studies [12,15,21,23,48,53].
By combining information on exposure and effect size,
it is believed that the PAF calculations shed an impor-
tant light on the types of interventions most likely to
increase coverage of IPTp.
This study is believed to be the first to use nationally
representative survey data to assess determinants of
provider’s delivery of IPTp during ANC consultations
and to quantify the potential impact of these deter-
minants. The use of standardized survey instruments
enabled the pooling of data from surveys conducted
in 1,285 facilities located in five countries. In addi-
tion, in comparison to other studies, an objectively
measured outcome was used in lieu of women’ss e l f -
report of IPTp uptake (which is often affected by re-
call bias) [61].
Conclusion
This study highlights a number of potential interven-
tions to increase coverage of IPTp. User-fees for ANC
medicines and facilities not having implemented routine
IPTp are two important barriers to IPTp delivery, but
these were relatively uncommon in the five surveyed
countries. Close to half of facilities lack IPTp-specific
guidelines/protocols but providing such items to all fa-
cilities would not increase delivery of this intervention
substantially. In contrast, interventions aiming at im-
proving the supply-chain management for SP to prevent
stock-outs would have some impact, although modest, on
delivery of IPTp. A quasi-experimental study conducted
in the Zambia has shown that simple structural and infor-
mation flow changes can lead to important improvements
in the availability of drugs [62]. It is doubtful, however,
that SP stock-outs could be entirely eliminated, especially
in countries where parts of health budgets are contingent
upon external funding [63]. As such, the proportional in-
crease in IPTp delivery that was estimated should be in-
terpreted as a theoretical upper bound. One of the most
interesting findings of this study was that training of pro-
viders could lead to important increases in IPTp delivery.
Only 30% of ANC consultations were offered by providers
who had received IPTp training during the year before the
survey, leaving room for improvements.
Interventions aimed at increasing knowledge and com-
petency of health workers are available and have shown
positive impacts on delivery of IPTp in Uganda [21] and
Kenya [23]. Future studies should evaluate the potential
of targeting interventions, either spatially in areas of low
IPTp coverage or to specific facilities. Private facilities,
health post and dispensary were shown to be less likely
to administer IPTp and should be prioritized to increase
coverage of this intervention. Multi-pronged approaches
are most likely to yield substantial increases in IPTp
coverage, and addressing providers’ barriers to effective
IPTp delivery is urgently required if the Roll Back Mal-
aria Partnership goal of 100% coverage by 2015 [13] and
the President’s Malaria Initiative target of 85% coverage
[14] are to be achieved.
Additional files
Additional file 1: Harmonization of the classification schemes for
type of facility and the provider’s qualification. This table provides
information on the different classification schemes for facility types and
provider’s qualifications were harmonized to be used in the pooled
analysis.
Additional file 2: Country-specific multivariable results of the
modified Poisson regression models of providers’ determinants of
delivery of intermittent preventive treatment for malaria in
pregnancy administered as directly observed therapy. Presented in
this table are the multivariable results when the regression models were
run separately for Kenya, Namibia, Rwanda, Tanzania, and Uganda.
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regression models, with fixed effect at the regional level, of
providers’ determinants of delivery of intermittent preventive
treatment for malaria in pregnancy (IPTp) administered as directly
observed therapy. This regression model controls for 60 dummy
variables that correspond to the different regions of the five surveyed
countries. Controlling for these regional variables had no effect on the
main determinants of IPTp delivery.
Additional file 4: Multivariable results of the modified Poisson
regression models of providers’ determinants of delivery of
intermittent preventive treatment for malaria in pregnancy
administered as directly observed therapy (IPTp) in facilities that
claim that this intervention is routinely offered as part of their
antenatal care services (ANC). Facilities that do not claim that IPTp is
part of their routine ANC services were excluded. Results show that this
has no impact on the main determinants of IPTp delivery.
Additional file 5: Proportional increase attributable to selected
modifiable determinants of intermittent preventive treatment for
malaria in pregnancy (IPTp, administered as directly observed
therapy) for Kenya, Namibia, Rwanda, Tanzania, and Uganda. The
proportional increase in IPTp delivery was calculated using the
population attributable fraction for each country separately.
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